Summary & Overview
CPT 53850: Microwave Thermotherapy for Benign Prostatic Hyperplasia
CPT code 53850 represents microwave thermotherapy for benign prostatic hyperplasia (BPH), a minimally invasive thermal ablation procedure that applies microwave energy to reduce enlarged prostatic tissue and relieve urethral obstruction. The code matters nationally as BPH is a common condition among aging men and thermal therapies are an alternative to pharmacologic management and traditional surgery, affecting utilization patterns, facility practice, and payer coverage decisions.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers can expect an overview of clinical context, typical sites of service, and common coding and billing considerations for CPT code 53850. The publication provides benchmarks for utilization and coverage trends, summarizes relevant policy updates that affect reimbursement pathways, and outlines clinical indications and limitations relevant to billing and prior authorization workflows.
This summary is intended for a national audience of coding managers, clinicians, and payer policy analysts who need concise information on the code's clinical purpose, service delivery context, and payer coverage implications. Data not provided in the input is noted where applicable.
Billing Code Overview
CPT code 53850 describes microwave thermotherapy of the prostate for benign prostatic hyperplasia (BPH). The procedure uses microwave energy to apply heat to enlarged prostatic tissue to reduce tissue volume and relieve urethral obstruction while providing protective cooling of the urethral mucosa.
Service type: minimally invasive thermal ablation therapy for BPH.
Typical site of service: outpatient surgical center or hospital outpatient department, performed under local or regional anesthesia with monitoring; some cases may occur in ambulatory surgery centers depending on facility capability.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with symptomatic benign prostatic hyperplasia (BPH) presents with progressive lower urinary tract symptoms (LUTS): urinary frequency, nocturia, weak urinary stream, and intermittent urinary retention. Medical management with alpha-blockers and 5-alpha-reductase inhibitors provided partial relief but symptoms persisted with bothersome obstructive features and recurrent urinary retention requiring catheterization. After urologic evaluation including digital rectal exam, urinalysis, post-void residual measurement, serum PSA assessment, and discussion of treatment options, the patient elects for minimally invasive microwave thermotherapy for reduction of prostatic tissue.
The clinical workflow includes pre-procedure clearance (assessment of anticoagulation status, informed consent, and baseline post-void residual), administration of local or regional anesthesia with conscious sedation as appropriate, placement of a transurethral microwave applicator with urethral cooling, delivery of microwave energy to targeted prostatic zones under urologist supervision, short post-procedure monitoring for urinary retention and hematuria, catheter placement if indicated, and follow-up visits to assess symptom improvement and post-void residual. Typical sites of service are an outpatient ambulatory surgical center or hospital outpatient department depending on patient comorbidities and payer requirements. The service type is a minimally invasive therapeutic procedure for BPH using microwave energy to ablate prostatic tissue, coded to 53850.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|